# Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension

> **NCT02951429** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 177 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** Placebo
- **DRUG:** Sildenafil

## Key facts

- **NCT ID:** NCT02951429
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-31
- **Primary completion:** 2019-09-26
- **Final completion:** 2020-08-22
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2020-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951429, "Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02951429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*